Renaissance Technologies (RenTech)'s ORMP Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 147,500 shares of Oramed Pharmaceuticals Inc. (ORMP) worth $420,375, representing 0.00% of the portfolio. First purchased in 2017-Q2, this long-term strategic position has been held for 32 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in ORMP, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2022, adding 359,697 shares. Largest reduction occurred in Q1 2021, reducing 372,415 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Oramed Pharmaceuticals (ORMP) Holding Value Over Time
Track share changes against reported price movement
Quarterly Oramed Pharmaceuticals (ORMP) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -1,400 | Reduce 0.94% | 147,500 | $2.85 |
| Q3 2025 | +4,700 | Add 3.26% | 148,900 | $2.64 |
| Q2 2025 | +1,700 | Add 1.19% | 144,200 | $2.25 |
| Q1 2025 | -9,308 | Reduce 6.13% | 142,500 | $2.14 |
| Q4 2024 | -93,492 | Reduce 38.11% | 151,808 | $2.42 |
| Q3 2024 | +14,500 | Add 6.28% | 245,300 | $2.44 |
| Q2 2024 | +108,700 | Add 89.03% | 230,800 | $2.57 |
| Q1 2024 | -218,973 | Reduce 64.20% | 122,100 | $2.92 |
| Q4 2023 | +296,773 | Add 669.92% | 341,073 | $2.31 |
| Q3 2023 | +10,600 | Add 31.45% | 44,300 | $2.62 |
| Q2 2023 | +21,800 | Add 183.19% | 33,700 | $0.00 |
| Q1 2023 | +11,900 | New Buy | 11,900 | $0.00 |
| Q3 2022 | -359,697 | Sold Out | 0 | $0.00 |
| Q2 2022 | +359,697 | New Buy | 359,697 | $4.58 |
| Q1 2022 | -203,200 | Sold Out | 0 | $0.00 |
| Q4 2021 | +203,200 | New Buy | 203,200 | $14.28 |
| Q1 2021 | -372,415 | Sold Out | 0 | $0.00 |
| Q4 2020 | -96,200 | Reduce 20.53% | 372,415 | $4.24 |
| Q3 2020 | +244,300 | Add 108.91% | 468,615 | $2.61 |
| Q2 2020 | +35,900 | Add 19.05% | 224,315 | $3.53 |
| Q1 2020 | -39,310 | Reduce 17.26% | 188,415 | $3.04 |
| Q4 2019 | +15,800 | Add 7.46% | 227,725 | $5.15 |
| Q3 2019 | +53,827 | Add 34.05% | 211,925 | $3.19 |
| Q2 2019 | +53,043 | Add 50.49% | 158,098 | $3.59 |
| Q1 2019 | +46,527 | Add 79.50% | 105,055 | $3.64 |
| Q4 2018 | +17,683 | Add 43.29% | 58,528 | $3.01 |
| Q3 2018 | -12,255 | Reduce 23.08% | 40,845 | $4.87 |
| Q2 2018 | -16,700 | Reduce 23.93% | 53,100 | $7.44 |
| Q1 2018 | -23,700 | Reduce 25.35% | 69,800 | $6.50 |
| Q4 2017 | +10,500 | Add 12.65% | 93,500 | $9.01 |
| Q3 2017 | +57,900 | Add 230.68% | 83,000 | $9.93 |
| Q2 2017 | +25,100 | New Buy | 25,100 | $7.77 |
Renaissance Technologies (RenTech)'s Oramed Pharmaceuticals Investment FAQs
Renaissance Technologies (RenTech) first purchased Oramed Pharmaceuticals Inc. (ORMP) in Q2 2017, acquiring 25,100 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Oramed Pharmaceuticals Inc. (ORMP) for 32 quarters since Q2 2017.
Renaissance Technologies (RenTech)'s largest addition to Oramed Pharmaceuticals Inc. (ORMP) was in Q2 2022, adding 359,697 shares worth $1.65 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 147,500 shares of Oramed Pharmaceuticals Inc. (ORMP), valued at approximately $420,375.
As of the Q4 2025 filing, Oramed Pharmaceuticals Inc. (ORMP) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Oramed Pharmaceuticals Inc. (ORMP) was 468,615 shares, as reported at the end of Q3 2020.